Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002

Status unconfirmed

Conditions studied: X-linked Hypohidrotic Ectodermal Dysplasia

In brief

The goal of the ECP-002e extension study is to continue the evaluation of all EDI200-treated ECP-002 subjects up to age 10 yrs. No additional study drug administration is planned. The efficacy evaluations will incorporate growth and development parameters, frequency of infections and hospitalizations, and age-appropriate assessments of ectoderm-derived organ function. The safety evaluations will include physical examinations, adverse events and concomitant medication documentation, and laboratory testing. Funding Source - FDA OOPD

Key facts

Study ID
NCT01992289
Run by
Edimer Pharmaceuticals
People needed
10
Starts
2014-03-01
Expected to finish
2025-03-01
Last updated by the study team
2017-09-05

Who can join

Age: 1 and older, up to 1. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.